Ocugen, a company working on new eye treatments, shared its progress in 2024. They're developing gene therapies to help people with eye diseases like retinitis pigmentosa and Stargardt disease. These treatments could be a one-time fix instead of many injections.
- They are testing three different treatments: OCU400, OCU410ST, and OCU410.
- Early results look promising, with some showing improved vision.
- They aim to get approval for three new treatments within the next few years.
| Treatment | Disease | Goal |
|---|---|---|
| OCU400 | Retinitis pigmentosa | Approval in 2026 |
| OCU410ST | Stargardt disease | Approval in 2027 |
| OCU410 | Age-related macular degeneration | Approval in 2028 |
